Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05064059
Title	A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Merck Sharp & Dohme Corp.
Indications	colorectal adenocarcinoma
Therapies	Regorafenib + Trifluridine-tipiracil hydrochloride MK-4280A
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| NOR \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| AUS